Fortrea Holdings (FTRE) Other Non-Current Assets (2022 - 2026)
Fortrea Holdings (FTRE) posted Other Non-Current Assets of $86.1 million for Q1 2026, up 6.56% on a QoQ basis from $80.8 million in Q4 2025, and down 15.09% year-over-year from $101.4 million in Q1 2025.
Fortrea Holdings (FTRE) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Fortrea Holdings' Other Non-Current Assets history runs 5 years deep, the most recent figure standing at $86.1 million for Q1 2026.
- Quarterly Other Non-Current Assets fell 15.09% year-over-year to $86.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.1 million (down 15.09% YoY) and the FY2025 annual result came in at $80.8 million, down 21.86% from the prior year.
- Other Non-Current Assets was $86.1 million for Q1 2026 at Fortrea Holdings, up from $80.8 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $345.1 million in Q1 2024 and bottomed at $54.3 million in Q4 2022.
- A 5-year average of $106.3 million and a median of $83.7 million in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets surged 49.64% — and 2025, when it sank 70.62%.
- Fortrea Holdings' Other Non-Current Assets stood at $54.3 million in 2022, then grew by 27.26% to $69.1 million in 2023, then surged by 49.64% to $103.4 million in 2024, then declined by 21.86% to $80.8 million in 2025, then increased by 6.56% to $86.1 million in 2026.
- Business Quant data shows FTRE's Other Non-Current Assets at $86.1 million in Q1 2026, $80.8 million in Q4 2025, and $74.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | 86.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.10 Mn |
| Dec 31, 2025 | 80.80 Mn |
| Sep 30, 2025 | 74.20 Mn |
| Jun 30, 2025 | 101.30 Mn |
| Mar 31, 2025 | 101.40 Mn |
| Dec 31, 2024 | 103.40 Mn |
| Mar 31, 2024 | 345.10 Mn |
| Dec 31, 2023 | 69.10 Mn |
| Sep 30, 2023 | 69.70 Mn |
| Jun 30, 2023 | 83.70 Mn |
| Dec 31, 2022 | 54.30 Mn |